11 results about "Diarrhea symptoms" patented technology

The application discloses a composition, which comprises hydrolyzed protein; the hydrolyzed protein comprises hydrolyzed whey protein and hydrolyzed casein protein, the weight ratio of the hydrolyzed whey protein and the hydrolyzed casein protein is (70-95):(5-30), the amino acid nitrogen content in the hydrolyzed protein is (1.0-3.0) g / 100 g, the proportion of protein hydrolysate with a relative molecular mass distribution <1000 in the hydrolyzed protein is 34-70%, the peptide content (calculated on a dry basis) in the hydrolyzed protein is not less than 33 g / 100 g, and the total free amino acid content in the hydrolyzed protein is not less than 1 g / 100 g. The composition can effectively treat diarrhea and is suitable for people with gastrointestinal dysfunction and severe patients with diarrhea symptoms.

The invention discloses a Saccharomyces cerevisiae strain with an intestinal tract probiotic function, the Saccharomyces cerevisiae strain is named as GLMQ-1, the classification name is Saccharomyces cerevisiae, the preservation number is CGMCC NO.34261, the preservation date is April 18, 2025, and the preservation unit is China General Microbiological Culture Collection Center, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The saccharomyces cerevisiae is separated from yak yoghurt in Qinghai province, has relatively strong acid and cholate tolerance, has good co-aggregation capability on escherichia coli, staphylococcus aureus and candida albicans, and can relieve antibiotic-induced diarrhea symptoms of mice and improve the tolerance on antibiotic-related diarrhea. The saccharomyces cerevisiae disclosed by the invention can be used for preparing anti-diarrhea medicines or microecologics, and has a very wide application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to application of phosphatidylcholine in preparation of a medicine for preventing and treating porcine rotavirus infection. The application finds that phosphatidylcholine (PC) has significant antiviral activity in preventing and treating PoRVA infection. Experimental results show that PC can effectively inhibit PoRVA proliferation, reduce viral load, and then relieve diarrhea symptoms caused by PoRVA infection and reduce mortality. In addition, PC can also inhibit necrotic apoptosis induced by PoRVA infection, promote repair and maintenance of intestinal barrier integrity, reduce intestinal tissue damage, and reduce the risk of secondary infection. The above results show that PC has good therapeutic potential for PoRVA infection. At the same time, PC is safe in source, has good biocompatibility, and no obvious toxic side effects are observed within a reasonable dose range, and is suitable for prevention and / or treatment of PoRVA infection, and has good application prospect and popularization value.

The invention discloses an application of a phthalocyanine compound and a delivery system thereof in preparation of an anti-clostridium difficile toxin drug, and discovers that phthalocyanine can specifically target TFPI, CSPG4 and FZD1, 2, 7 receptor binding domains of clostridium difficile toxin B (TcdB), and effectively inhibits binding of toxin and host cells. In-vitro experiments prove that the phthalocyanine (Phthalocyanine, Pc) can be used for remarkably relieving the cytopathy induced by TcdB and has no cytotoxicity. In order to improve the curative effect, an extracellular vesicle (S-EV) from saccharomyces boulardii is creatively adopted to construct a drug loading system S-EV-Pc, and the pH responsive intestinal targeted delivery of the drug is realized. Animal experiments show that the preparation can significantly improve the survival rate of infected gerbil to 100%, significantly improve diarrhea symptoms, reduce intestinal TcdB load and relieve tissue pathological damage. The invention discloses the potential of phthalocyanine as a non-antibiotic small molecule drug in treatment of clostridium difficile infection (CDI) for the first time, and provides a brand new strategy and an experimental basis for developing a novel anti-CDI preparation.

The application discloses the application of Shaoyao Gancao Decoction in the preparation of a drug for treating chemotherapy-related diarrhea, and belongs to the technical field of medical applications. The application provides the application of Shaoyao Gancao Decoction in the preparation of a drug for treating chemotherapy-related diarrhea, wherein the chemotherapy-related diarrhea is intestinal toxicity diarrhea induced by a chemotherapy drug. Shaoyao Gancao Decoction is a water decoction extract, which is obtained by soaking, reflux extraction, filtration, concentration and drying of Radix Paeoniae Alba and Radix Glycyrrhizae in a weight ratio of 1:1. Shaoyao Gancao Decoction can improve diarrhea symptoms, reduce diarrhea index, reduce perianal pollution, restore intestinal flora diversity, and realize the treatment effect on chemotherapy-related diarrhea by regulating the AhR / NF-κB signal pathway.

The application provides a method for differentiating pathogenic causes of diarrhea after allogeneic hematopoietic stem cell transplantation, and specifically provides application of a reagent for detecting a combination of biological indexes of an individual in preparation of a product for differentiating pathogenic causes of diarrhea after allogeneic hematopoietic stem cell transplantation, wherein the biological indexes include: absolute count of NK cells, CD4 + CD28 + T cells account for CD4 + T lymphocyte percentage; and the detection time point of the biological indexes is within seven days before the diarrhea symptom appears. The method for differentiating pathogenic causes of diarrhea after allogeneic hematopoietic stem cell transplantation provided by the application realizes minimally invasive, low-risk, early and accurate pathogenic cause differentiation by detecting peripheral blood samples and constructing a detection model in combination with multi-time point data.

The invention belongs to the technical field of health care products, and particularly relates to a composition for regulating intestinal flora and a preparation method and application thereof. The composition for regulating the intestinal flora is prepared from the following raw materials in parts by weight: 80 to 120 parts of fried rice flour, 25 to 35 parts of galactomannan, 5 to 15 parts of compound probiotic powder, 3 to 8 parts of pectin, 1 to 3 parts of glutathione and 5 to 10 parts of resistant dextrin. The composition provided by the invention not only can nourish beneficial bacteria through prebiotics, but also can directly supplement the beneficial bacteria through other components, protect intestinal mucosa, reduce inflammation and supplement electrolyte, so that diarrhea symptoms can be quickly improved from multiple targets, and the intestinal microecology can be regulated for a long time.

The invention provides a method for identifying and diagnosing pathogenic causes of diarrhea after transplantation of allogenic hematopoietic stem cells, and particularly provides application of a reagent for detecting a biological index combination of an individual in preparation of a product for identifying the pathogenic causes of diarrhea after transplantation of the allogenic hematopoietic stem cells, the biological indexes comprise the absolute count of NK cells and the percentage of CD4 + CD28 + T cells in CD4 + T lymphocytes; the detection time point of the biological indexes is within seven days before diarrhea symptoms appear. According to the diarrhea pathogenic cause differential diagnosis method after allogenic hematopoietic stem cell transplantation based on immune cell subpopulation and cell factor dynamic monitoring, a detection model is constructed through peripheral blood sample detection in combination with multi-time-point data, and minimally invasive, low-risk, early-stage and accurate pathogenic cause identification is achieved.

This invention belongs to the field of traditional Chinese medicine compositions, specifically relating to a traditional Chinese medicine composition for treating lung heat, its preparation method, and its application. The Xiebai Powder provided by this invention is composed of the following ingredients: Lycium chinense root bark, stir-fried mulberry bark, stir-fried licorice root, japonica rice, pickled apricot kernels, and Pinellia ternata. The formula provided by this invention is both clearing and moistening, purging while also tonifying, and tonifying while dispersing. The addition of pickled apricot kernels and Pinellia ternata makes it more suitable for the immature Yin and Yang constitution of children, addressing both cough and diarrhea symptoms, thus balancing the root cause and the symptoms. It aligns with the characteristics of the lungs being a delicate organ, intolerant to cold and heat, and children's weak spleen and stomach, making them prone to diarrhea and cough, thereby shortening the course of the disease and improving efficacy.

A computer system dealing with digestive health (such as diarrhea) can help guide users to content particularly relevant to their experience without requiring traditional user-input search terms. Such a system can receive user-specific time-series data indicating the user's recorded diet, mood, and diarrhea symptoms. This data can be captured in a daily journaling application on a smartphone. The system can use this data to determine the correlation between the user's recorded diet and mood information and the user's recorded diarrhea symptom information. Appropriate content units can then be selected from multiple content units based on the determined correlation, such as from a database of digestive health information. The selected units can then be presented to the user.

The invention relates to a traditional Chinese medicine composition for treating diarrhea and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The invention provides a traditional Chinese medicine composition for treating diarrhea. The traditional Chinese medicine composition comprises Chinese fevervine herb and humifuse euphorbia herb. The mass ratio of the Chinese fevervine herb to the humifuse euphorbia herb is (1-2): (1-2). An escherichia coli infectious diarrhea mouse model is established, the prevention and treatment effects of independent application and combined application of the Chinese fevervine herb and the humifuse euphorbia herb on the escherichia coli infectious diarrhea are evaluated, and results show that the diarrhea symptoms are relieved to different degrees by independent application of the Chinese fevervine herb and the humifuse euphorbia herb, and the Chinese fevervine herb and the humifuse euphorbia herb have a synergistic effect; through combined application, the diarrhea degree can be effectively relieved, the body state can be improved, inflammation caused by diarrhea can be relieved, meanwhile, weight gain can be promoted, and an experimental basis is provided for scientific application of traditional Chinese medicine in prevention and treatment of animal bacterial diarrhea.